tbuckley/cabot-search huggingface dataset:
Abstract 17096: Left Ventricular Dilatation and Increased Wall Thickness represent Early Echocardiographic Findings in Asymptomatic Alcoholics
Authors: Rahul Mehta, Costy Mattar, Nidhi P Mehta
Journal: Circulation (2013)

Introduction: Alcoholic cardiomyopathy is a major cause of secondary non-ischemic cardiomyopathy. Early alcoholic cardiomyopathy is asymptomatic and reversible, and changes in heart structure and function at this stage can be characterized by 2-dimensional and Doppler echocardiography. Methods: 40 asymptomatic alcoholics who had consumed alcohol equivalent to 60 grams of pure ethanol per day, at least 5 days a week for 5 years or more; and 40 age and sex matched controls underwent 2-dimensional and Doppler echocardiography. Alcoholics were divided based on amount of alcohol consumed (moderate drinkers: 60-100 grams/day and heavy drinkers: more than 100 grams/day), and the duration of alcohol consumed (short: 5-9 years, intermediate: 10-15 years and long: 16-28 years). Results: Asymptomatic alcoholics had higher left ventricular internal dimension, end diastole (LVIDD) (p <0.0001), and left ventricular internal dimension, end systole (LVIDS) (p <0.05) compared to controls. Even short term (5-9 years) alcoh...
Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
Authors: K. J. O'Byrne, I. Bondarenko, C. Barrios, C. Eschbach, U. Martens, Y. Hotko, C. Kortsik, I. Celik, C. Stroh, R. Pirker
Journal: Journal of Clinical Oncology (2009)

8007 Background: The multinational, randomized, phase III FLEX study compared cisplatin/vinorelbine (CT) plus the EGFR- antibody, cetuximab (Erbitux), with CT alone in the 1st-line treatment of patients (pts) with advanced EGFR-expressing NSCLC and demonstrated a statistically significant OS benefit for the cetuximab combination. We hypothesized that KRAS mutation status is predictive for cetuximab efficacy and enables optimal use of cetuximab. The relationship between early-onset acne-like rash (ie rash that developed ≤21 days of treatment initiation) and OS time of pts treated with CT and cetuximab was also evaluated. Methods: Archived tumor samples from 554/1125 pts were available. Genomic DNA derived from formalin-fixed paraffin embedded tumor tissue was analyzed for KRAS using an LNA-mediated qPCR clamping assay capable of detecting oncogenic mutations at codons 12 and 13. The Kaplan-Meier method was used to estimate OS time and PFS time in pts with KRAS wild-type (wt) and mutant (mt) tumors for each treatment arm. All pts treated with cisplatin/vinorelbine plus cetuximab who were alive at 21 days were included in a landmark analysis evaluating the relationship between early-onset acne-like rash and OS time. Results: KRAS results were obtained from 379 pts. A KRAS mutation was detected in 72 (19%) pts. The comparison of the cetuximab treatment effects in pts with KRAS wt tumors and pts with KRAS mt tumors showed no marked differences with regard to OS or PFS. A total of 518 pts were included in the landmark analysis. Pts treated with cetuximab who developed early acne-like rash of any grade (grade 1–3; 56%, n=290) had a longer median OS than those without acne-like rash (n=228) (median [95% CI]: 15.0 months [12.8–16.4] vs 8.8 months [7.6–11.1]; HR [95% CI]: 0.63 [0.52–0.77]; p&lt;0.001). Analysis of EGFR FISH is ongoing and results will be presented. Conclusions: Clinical data from the FLEX study do not support the hypothesis that KRAS mutation status is predictive for cetuximab efficacy when combined with 1st- line chemotherapy in advanced NSCLC, whereas early acne-like rash of any grade appears to be associated with better outcome in pts treated with platinum-based chemotherapy plus cetuximab in this setting. [Table: see text]
Is painful knee an independent predictor of mortality in middle-aged women?
Authors: Shu-Guang Gao, Chao Zeng, Yi-lin Xiong, Jie Wei, Guang-Hua Lei
Journal: Annals of the Rheumatic Diseases (2016)

We read with deep interest the article by Kluzek et al ,1 which examined whether joint pain or radiographic osteoarthritis (ROA) of the knee and hand is associated with the all-cause and disease-specific mortality in middle-aged women. The outcome of this prospective community-based Chingford Cohort Study indicated a significantly increased risk of all-cause and cardiovascular disease-specific mortality in women experiencing knee pain with or without ROA, but not in women with ROA alone. It suggests that knee pain, rather than structural changes of osteoarthritis (OA), can be considered as an independent predictor of mortality in middle-aged women. We sincerely appreciate the work performed and the valuable findings obtained by the authors; nevertheless, some issues are worth of further exploration.

First, knee pain was selected as an important evaluative parameter to predict mortality in middle-aged women in this study, but there were several factors that can cause knee pain. A substantial part of knee pain might be related to the knee joint itself and another source of knee pain might result from other musculoskeletal diseases. The most common cause of knee pain is an injury, which can …
BCR-ABL1 Molecular Remission After 90y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22+ Ph+ B-ALL: A Potential New Treatment Paradigm
Authors: Patrice Chevallier, Caroline bodet-Milin, Nelly Robillard, Thomas Eugene, Audrey Ménard, Claire Le Houerou, Thierry Guillaume, Jacques Delaunay, Martine Escoffre-Barbe, William A Wegener, David M Goldenberg, Françoise kraeber-Bodere
Journal: Blood (2013)
Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization
Authors: Renato D. Lopes, Sergio Leonardi, Benjamin Neely, Megan L. Neely, E. Magnus Ohman, Diego Ardissino, Christian W. Hamm, Shaun G. Goodman, Deepak L. Bhatt, Harvey D. White, Dorairaj Prabhakaran, Felipe Martinez, Jose C. Nicolau, Kenneth J. Winters, Keith A.A. Fox, Paul W. Armstrong, Matthew T. Roe
Journal: Journal of the American College of Cardiology (2016)
Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study.
Authors: R Nitschke, E I Smith, S Shochat, G Altshuler, H Travers, J J Shuster, F A Hayes, R Patterson, N McWilliams
Journal: Journal of Clinical Oncology (1988)

A prospective study was designed to evaluate the outcome of patients with localized resectable neuroblastoma without regional lymph node involvement when no therapy beyond surgical resection was administered. One hundred one patients observed for 3 to 60 months had a 2-year disease-free survival of 89% (SE = 5%). Of the nine patients experiencing relapse, only three have died. There were no apparent distinguishing characteristics of the nine failures. Due to the favorable prognosis of the subset of neuroblastoma patients, prognostic factor analysis had very limited power and lacked clinical importance. Complete gross removal of the localized tumors is adequate therapy to ensure the survival of the majority of these patients.
Prosociality and religion: History and experimentation
Authors: Benjamin Beit-Hallahmi
Journal: Behavioral and Brain Sciences (2016)

Abstract Norenzayan et al. are praised for choosing to deal with significant questions in the understanding of religion. They are then criticized for refusing to define religion and for relying on problematic theoretical concepts. The authors discuss Abrahamic religions as the best-known prosocial religions, but the evidence shows that the case does not fit their conceptual framework. Finally, an extension of the authors’ ideas about the meaning of priming effects is proposed.
Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study
Authors: Olivia M Farr, Michael A Tsoukas, Georgios Triantafyllou, Fadime Dincer, Andreas Filippaios, Byung-Joon Ko, Christos S Mantzoros
Journal: Metabolism (2016)
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Authors: Christopher P. Evans, Celestia S. Higano, Thomas Keane, Gerald Andriole, Fred Saad, Peter Iversen, Kurt Miller, Choung-Soo Kim, Go Kimura, Andrew J. Armstrong, Cora N. Sternberg, Yohann Loriot, Johann de Bono, Sarah B. Noonberg, Hank Mansbach, Suman Bhattacharya, Frank Perabo, Tomasz M. Beer, Bertrand Tombal
Journal: European Urology (2016)
Correction: In situ induction of dendritic cell–based T cell tolerance in humanized mice and nonhuman primates
Authors: Kyeong Cheon Jung, Chung-Gyu Park, Yoon Kyung Jeon, Hyo Jin Park, Young Larn Ban, Hye Sook Min, Eun Ji Kim, Ju Hyun Kim, Byung Hyun Kang, Seung Pyo Park, Youngmee Bae, Il-Hee Yoon, Yong-Hee Kim, Jae-Il Lee, Jung-Sik Kim, Jun-Seop Shin, Jaeseok Yang, Sung Joo Kim, Emily Rostlund, William A. Muller, Seong Hoe Park
Journal: The Journal of Experimental Medicine (2016)

The authors regret that a measurement was incorrect and that the source of the 5C8 clone was left out of the original publication.The corrected sentence in the Results section MD-3 efficiently induces antigen-specific T cell tolerance in nonhuman primates appears below."However, long-term graft survival was finally achieved with a combination treatment of low-dose rapamycin (trough level 6-12 ng/ml) and mouse-human IgG1 chimeric anti-human CD154 blocking antibody (5C8 clone derivative; National Institutes of Health Nonhuman Primate Reagent Resource), as well as MD-3."
P151 Tiotropium Respimat® add-on therapy reduces exacerbation risk in patients with moderate or severe symptomatic asthma, independent of TH2 status: Abstract P151 Table 1
Authors: T Casale, R Dahl, JC Virchow, M Engel, P Moroni-Zentgraf, R Lühmann, HAM Kerstjens
Journal: Thorax (2015)

<h3>Background</h3> Phase III studies have demonstrated reduced exacerbation rates with tiotropium Respimat® (tioR) add-on to ICS + LABA in patients with symptomatic asthma (Kerstjens <i>et al</i>. NEJM 2012;367:1198–207). There are currently no reported specific treatments for asthma that work equally well in both T<sub>H</sub>2-low and T<sub>H</sub>2-high phenotypes. We explored, in patients with moderate or severe symptomatic asthma, whether T<sub>H</sub>2 status influenced tioR responses, assessed by time to first exacerbation. <h3>Methods</h3> In two 48-week trials (PrimoTinA-asthma®: NCT00776984/NCT00772538), patients on ICS + LABA (≥800 µg budesonide or equivalent) received once-daily tioR 5 µg or placebo Respimat®. In two 24-week trials (MezzoTinA-asthma®: NCT01172808/NCT01172821), patients on ICS (400–800 µg budesonide or equivalent) received once-daily tioR 5 µg or 2.5 µg, twice-daily salmeterol 50 µg via hydrofluoroalkane metered-dose inhaler (active comparator) or placebo (identical devices in a double-dummy protocol). Pre-planned analyses (pooled data) of time to first severe exacerbation and time to first episode of asthma worsening were performed in T<sub>H</sub>2-low and T<sub>H</sub>2-high subgroups: total serum immunoglobulin (IgE) ≤ or &gt;430 µg/L (179.2 IU/L); blood eosinophils ≤ or &gt;0.6 × 10<sup>9</sup>/L (600/μL). <h3>Results</h3> 912 patients with severe asthma received tioR 5 µg or placebo Respimat®: 205/182 were reported with IgE &gt;430 µg/L and 99/87 with an eosinophil count of &gt;0.6 × 10<sup>9</sup>/L. 2100 patients with moderate asthma received tioR 5 µg or 2.5 µg, salmeterol or placebo: 319/320/319/326 were reported with IgE &gt;430 µg/L and 104/103/111/107 with an eosinophil count of &gt;0.6 × 10<sup>9</sup>/L. Time to first severe exacerbation was longer with tioR versus placebo (Table 1) in patients with severe or moderate asthma, independent of IgE and eosinophils (interaction p values [Cox regression] 0.169 and 0.754, respectively, for PrimoTinA-asthma®; analyses not performed for MezzoTinA-asthma® because of low incidence of severe exacerbations). Time to first asthma worsening was longer with tioR versus placebo (Table 1) in patients with moderate or severe asthma, independent of IgE (interaction p values 0.998 [PrimoTinA-asthma®] and 0.041 [MezzoTinA-asthma®]) and eosinophils (interaction p values 0.251 [PrimoTinA-asthma®] and 0.125 [MezzoTinA-asthma®]). <h3>Conclusion</h3> Once-daily tiotropium Respimat® add-on to at least ICS reduced the risk of severe exacerbation and asthma worsening in patients with moderate or severe symptomatic asthma, independent of T<sub>H</sub>2 phenotype.
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Authors: Scott A. Foster, Daniel M. Whalen, Ayşegül Özen, Matthew J. Wongchenko, JianPing Yin, Ivana Yen, Gabriele Schaefer, John D. Mayfield, Juliann Chmielecki, Philip J. Stephens, Lee A. Albacker, Yibing Yan, Kyung Song, Georgia Hatzivassiliou, Charles Eigenbrot, Christine Yu, Andrey S. Shaw, Gerard Manning, Nicholas J. Skelton, Sarah G. Hymowitz, Shiva Malek
Journal: Cancer Cell (2016)
Capecitabine and oxaliplatin in advanced colorectal cancer: A dose-finding study
Authors: M Zeuli, E Di Costanzo, A Sdrobolini, S Gasperoni, F P Paoloni, A Carpi, L Moscetti, R Cherubini, F Cognetti
Journal: Annals of Oncology (2001)

Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC). The aim of this dose-finding trial was to determine the maximum-tolerated dose (MTD), the dose-limiting toxicities (DLTs) and the activity of the combination in patients with advanced colorectal cancer.Twenty-five chemotherapy-pretreated patients received the combination of capecitabine and oxaliplatin. Capecitabine was administered orally twice a day continuously for 14 days in doses ranging from 1,650 to 2,500 mg/m2/d, and oxaliplatin was administered as a two-hour infusion on day 1 using dose, ranges from 100 to 130 mg/m2 repeated every three weeks.Twenty-five patients were assessable for toxicity, and DLTs were diarrhea (grade > or = 3: 27%) and stomatitis (grade > or = 3: 9%) at dose level VI. Dose level V (capecitabine 2500 mg/m2 and oxaliplatin 120 mg/m2) was found to be the MTD. Hematological toxicity was minimal, overall neurotoxicity (grade 1-4) was 27% with 1% grade 3-4. A global response rate was 17% (95% confidence interval (95% CI): 2%-32%) and the median overall survival was 12 months.The recommended dose for further phase II studies is capecitabine 2,500 mg/m2/d with intermittent schedule and oxaliplatin 120 mg/m2 every three weeks. The toxicities were mainly gastrointestinal: diarrhea, stomatitis and vomiting. This combination should be studied in phase II trials in advanced colorectal.
Lymphocyte Transformation in Children With Neuroblastoma 1 2
Authors: Lawrence Helson, Lien Shou, Jurg Tauber
Journal: JNCI Journal of the National Cancer Institute (1976)

Using a simple fingerstick-whole blood technique, we demonstrated that patients with disseminated neuroblastoma have diminished lymphocyte responses to phytohemagglutinin (PHA) and that their sensitivity to antilymphocyte serum inhibition of PHA responses was increased over that of tumor-free controls. These altered immunologic reactivities led us to question the chronologic sequence between the occurrence of the tumor and the lymphocyte defect. Tumor-bearing patients had serum substances that exerted an inhibitory effect on the transformation responses of lymphocytes from unrelated normal individuals; these substances may be present in sera for long periods after the tumor is eliminated.
Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.
Authors: C. E. Almasi, I. J. Christensen, G. Høyer-Hansen, K. Danø, H. Pappot, H. Dienemann, T. Muley
Journal: Journal of Clinical Oncology (2010)

10518 Background: The plasminogen activation system is involved in extracellular proteolysis during cancer invasion. In addition to the generation of plasminogen, urokinase (uPA) can cleave its cellular three-domain receptor, uPAR(I-III), between domain I and II, liberating domain I, uPAR(I), and leaving uPAR(II-III) on the cell surface. Both uPAR(I-III) and uPAR(II-III) can be shed from the cell. Recently, we found that high levels of both intact uPAR and its cleaved forms in blood from a small number (n = 32) of patients operated for non-small cell lung cancer (NSCLC) were associated with short overall survival (OS). The aim of the study was to investigate the prognostic impact of uPAR forms in serum from 171 NSCLC patients. Methods: Serum sampled preoperatively was available from 171 patients radically resected for NSCLC. uPAR(I-III), uPAR(I-III) plus uPAR(II-III) and uPAR(I) were measured by time-resolved fluoroimmunoassays. Results: High serum levels of each of the three uPAR forms were associated with short OS. In a multivariate survival analysis uPAR(l-lll) and uPAR(l) remained significant prognostic parameters independently of stage, histology, age, performance status and therapy, uPAR(l-lll) being the strongest (hazard ratio [HR] = 2.3, confidence interval [CI]: 1.2-4.5, p = 0.015). Conclusions: This retrospective study validate a previous study and shows that uPAR(l-lll) and uPAR(l) in serum are independent prognostic factors in patients radically operated for NSCLC. No significant financial relationships to disclose.
Response to Letter Regarding Article, “Upregulation of K <sub>2P</sub> 3.1 K <sup>+</sup> Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation”
Authors: Constanze Schmidt, Felix Wiedmann, Niels Voigt, Xiao-Bo Zhou, Jordi Heijman, Siegfried Lang, Virginia Albert, Stefan Kallenberger, Arjang Ruhparwar, Gábor Szabó, Klaus Kallenbach, Matthias Karck, Martin Borggrefe, Peter Biliczki, Joachim R. Ehrlich, István Baczkó, Patrick Lugenbiel, Patrick A. Schweizer, Birgit C. Donner, Hugo A. Katus, Dobromir Dobrev, Dierk Thomas
Journal: Circulation (2016)
Abstract 11857: Polypharmacy is Associated With Increased Long Term Risk of Recurrent Syncope
Authors: Martin H Ruwald, Morten Lock Hansen, Morten Lamberts, Christian Selmer, Michael Vinther Hojgaard, Lars Kober, Christian Torp-Pedersen, Jim Hansen, Gunnar H Gislason
Journal: Circulation (2012)

Background Recurrent syncope is a public health problem, and the association with polypharmacy is not fully elucidated. Objective To examine the relationship between the sum of medications and the ...
Angiotensin-converting enzyme inhibition reduces the effect of bromoethylamine-induced papillary necrosis and renal fibrosis.
Authors: S L Garber, Y Mirochnik, S S Desai, J A Arruda, G Dunea
Journal: Journal of the American Society of Nephrology (1998)

Rats injected with a single, 50-mg dose of bromoethylamine (BEA) developed papillary necrosis accompanied by sever interstitial fibrosis. At 1 mo, the creatinine clearance decreased (control 0.66 versus BEA 0.33 ml/min per 100 g body wt, P = 0.02), and the urine albumin-to-creatinine ratio increased markedly (control 0.19 versus BEA 0.51, P = 0.02). In a group of animals given the angiotensin-converting enzyme inhibitor enalapril (Enal; 100 mg/L) in their drinking water for 4 wk, beginning 1 wk before BEA injection, creatinine clearance improved significantly (BEA 0.33 versus Enal + BEA 0.52 ml/min per 100 g body wt, P = 0.01) and albumin excretion fell to zero. Histologic examination revealed an 88% decrease in the area of papillary necrosis and a decrease in the degree of interstitial fibrosis in the corticomedullary junction. To determine whether this was due to changes in urine flow rate induced by enalapril, a group of animals was injected with BEA, and enalapril at the above dose was begun 1 wk later. After 1 mo, the enalapril-treated animals showed the same improvement in creatinine clearance (BEA 0.33 versus BEA + Enal 0.50 ml/min per 100 g body wt, P = 0.03) and suppression of albumin excretion. The area of papillary necrosis was reduced by 67%. In the BEA animals treated with enalapril, ED-1-positive cells, alpha-smooth muscle actin, and transforming growth factor-beta1 were decreased compared with BEA alone. It is concluded that in this model of papillary necrosis, enalapril protects renal function and decreases interstitial fibrosis mediated at least in part through an angiotensin II/bradykinin-dependent mechanism.
Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems
Authors: Dongdong Zhang, Jiaxi Wang, Donggang Xu
Journal: Journal of Controlled Release (2016)

Unique characteristics, such as nontoxicity and rapid cellular internalization, allow the cell-penetrating peptides (CPPs) to transport hydrophilic macromolecules into cells, thus, enabling them to execute biological functions. However, some CPPs have limitations due to nonspecificity and easy proteolysis. To overcome such defects, the CPP amino acid sequence can be modified, replaced, and reconstructed for optimization. CPPs can also be used in combination with other drug vectors, fused with their preponderances to create novel multifunctional drug-delivery systems that increase the stability during blood circulation, and also develop novel preparations capable of targeted delivery, along with sustainable and controllable release. Further improvements in CPP structure can facilitate the penetration of macromolecules into diverse biomembrane structures, such as the blood brain barrier, gastroenteric mucosa, and skin dermis. The ability of CPP to act as transmembrane vectors improves the clinical application of some biomolecules to treat central nervous system diseases, increase oral bioavailability, and develop percutaneous-delivery dosage form.
Bone marrow metastasis in solid tumors: Clinical evaluation of 64 cases
Authors: S. Kilickap, M. Erman, M. Dincer, S. Aksoy, H. Harputluoglu, S. Yalcin
Journal: Journal of Clinical Oncology (2005)

8270 Background: Bone marrow aspiration remains the easiest and cheapest method to document bone marrow metastases (BMM) of solid tumors. Methods: The results of bone marrow aspirates carried out in Hacettepe Institute of Oncology between 1993–2004 were reviewed. Hospital charts of solid tumor patients with an aspirate suggestive of a BMM were evaluated for associated clinical features. Results: Sixty-four patients (33 M, 31 F) were found to have BMM. Mean age ± SD was 50±13 years (range: 17–77). The most common diagnoses were breast (28%) and lung cancers (23%), followed by gastric (9%), prostate cancers (8%), and Ewing sarcomas (6%). Six patients (9%) had unknown primaries. Soft tissue sarcomas (3%), melanoma (1.6%), cancers of the nasopharynx (3%), larynx (1.6%), bladder (1.6%), rectum (1.6%), endometrium (1.6%), and testis (1.6%) were the other underlying tumors. Fifty-one percent of patients had BMM at diagnosis. Anemia and thrombocytopenia were present in 70% and 63% of patients, respectively, while neutropenia was less common (22%). Eight percent of patients had normal blood counts and 17% were pancytopenic. Mean hemoglobin was 10.5±2.4 g/dl (range: 5.9–16.5), WBC 8,100±6,700/mm3 (range: 2,200–44,800), and platelet 176,000±166,000/mm3 (range: 9,000–837,000). Bone metastasis was the most frequently associated clinical feature (72%). Median survival after the detection of BMM was 2 months (95% confidence interval: 0.7–3.3). One-year survival was only 14%. Conclusions: Breast and lung carcinomas are the most common causes BMM. Prostate cancer is also commonly associated with BMM, however, few patients with prostate cancer are followed in our clinic, and this may have altered our results. Blood counts may be variable, but commonly show moderately depressed counts in one or two of the lineages. Occasional patients may have totally normal counts. This condition carries an extremely poor prognosis. No significant financial relationships to disclose.